Grant: Discovery Grants Program - Individual
University of Toronto
$35,000.00
Oligomeric structure and membrane disruption by an amyloid peptide from the mammalian prion protein
EF 2009-10
Résumé
The accumulation of misfolded or aggregated protein in a fibrillar form is characteristic of several human diseases including amyloid diseases, such as type II diabetes and Alzheimer's disease, as well as spongiform encephalopathies (prion diseases). These diseases are related to the misfolding of different proteins, and exhibit different mechanisms for infectivity, however growing evidence points to a common mechanism for the cytotoxicity of the misfolded proteins. Specifically, it has been proposed that cell death is caused by small protein aggregates. Recent studies have indicated that these toxic aggregates are able to directly kill cells by disrupting their membranes; possibly through formation of channels or holes in the plasma membrane, or simply by inducing leakage of cell contents, and that this leads to cell death and progression of the disease state. In order to unravel this common mechanism for amyloid protein toxicity, we will characterize the molecular structure and membrane-binding behaviour of a neurotoxic fragment of the mammalian prion protein (PrP). In addition to forming amyloid fibrils, PrP(106-126) has been shown to form small, neurotoxic aggregates and to disrupt membranes, making it a suitable model for our studies. Using solid state nuclear magnetic resonance (NMR), we will determine the molecular structure of the toxic aggregates formed by this peptide, and define the interactions of PrP(106-126) with model cell membranes. Specifically, we will:
(1) Determine the structure of oligomers formed by PrP(106-126).
(2) Define the structures formed by PrP(106-126) in lipid bilayers.
(3) Characterize the effects of PrP(106-126) on membrane integrity.
This research will provide the first high-resolution details of the structure of the toxic form of an amyloid-forming peptide, and will illustrate the biophysical basis for protein-lipid interactions which contribute to increased permeability of cell membranes and thus to cytotoxicity in diseases of protein aggregation.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
342069-2007
Name nom
Sharpe, Simon
Department département
Biochemistry
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2009
Competition year année de concours
2007
Award amount
35000
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
32
Committee name en
Cell Biology
Committee name fr
Biologie cellulaire
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
5403
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Proteins and peptides, amino acids
Research subject fr
Protéines et peptides, acides aminés
Partie
3
Nb partie
5
Application title
Oligomeric structure and membrane disruption by an amyloid peptide from the mammalian prion protein
Keyword
NA
Application summary
The accumulation of misfolded or aggregated protein in a fibrillar form is characteristic of several human diseases including amyloid diseases, such as type II diabetes and Alzheimer's disease, as well as spongiform encephalopathies (prion diseases). These diseases are related to the misfolding of different proteins, and exhibit different mechanisms for infectivity, however growing evidence points to a common mechanism for the cytotoxicity of the misfolded proteins. Specifically, it has been proposed that cell death is caused by small protein aggregates. Recent studies have indicated that these toxic aggregates are able to directly kill cells by disrupting their membranes; possibly through formation of channels or holes in the plasma membrane, or simply by inducing leakage of cell contents, and that this leads to cell death and progression of the disease state. In order to unravel this common mechanism for amyloid protein toxicity, we will characterize the molecular structure and membrane-binding behaviour of a neurotoxic fragment of the mammalian prion protein (PrP). In addition to forming amyloid fibrils, PrP(106-126) has been shown to form small, neurotoxic aggregates and to disrupt membranes, making it a suitable model for our studies. Using solid state nuclear magnetic resonance (NMR), we will determine the molecular structure of the toxic aggregates formed by this peptide, and define the interactions of PrP(106-126) with model cell membranes. Specifically, we will:
(1) Determine the structure of oligomers formed by PrP(106-126).
(2) Define the structures formed by PrP(106-126) in lipid bilayers.
(3) Characterize the effects of PrP(106-126) on membrane integrity.
This research will provide the first high-resolution details of the structure of the toxic form of an amyloid-forming peptide, and will illustrate the biophysical basis for protein-lipid interactions which contribute to increased permeability of cell membranes and thus to cytotoxicity in diseases of protein aggregation.